Rational Drug Design: Methods and Protocols (Record no. 295589)

MARC details
000 -LEADER
fixed length control field 03778nam a2200169Ia 4500
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781627030076
082 ## - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 615.1/9 RAT
100 ## - MAIN ENTRY--PERSONAL NAME
Personal name Yi Zheng
245 ## - TITLE STATEMENT
Title Rational Drug Design: Methods and Protocols
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Place of publication, distribution, etc. New York
Name of publisher, distributor, etc. Humana Press
Date of publication, distribution, etc. 2012
300 ## - PHYSICAL DESCRIPTION
Extent xi, 230 pages : illustrations (some color) ; 27 cm.
490 ## - SERIES STATEMENT
Series statement Methods in molecular biology (Clifton, N.J.), v. 928.; Springer protocols (Series)
505 ## - FORMATTED CONTENTS NOTE
Formatted contents note On setting up and assessing docking simulations for virtual screening / Jacek Biesiada, Aleksey Porollo, and Jaroslaw Meller -- Virtual ligand screening combined with NMR to identify Dvl PDZ domain inhibitors targeting the Wnt signaling / Jufang Shan and Jie J. Zheng -- Rational design of Rho GTPase-targeting inhibitors / Xun Shang and Yi Zheng -- Rational design of peptide ligands against a glycolipid by NMR studies / Wenyong Tong [and others] -- Combinatorial strategy for the acquisition of potent and specific protein tyrosine phosphatase inhibitors / Sheng Zhang [and others] -- Identification of allosteric inhibitors of p21-activated kinase / Julien Viaud and Jeffrey R. Peterson -- Using a modified yeast two-hybrid system to screen for chemical GEF inhibitors / Anne Blangy and Philippe Fort -- Random mutagenesis of peptide aptamers as an optimization strategy for inhibitor screening / Nathalie Bouquier [and others] -- Screening strategy for trapping the inactive conformer of a dimeric enzyme with a small molecule inhibitor / Charles S. Craik and Tina Shahian -- Use of a fluorescent ATP analog to probe the allosteric conformational change in the active site of the protein kinase PDK1 / Valerie Hindie, Laura A. Lopez-Garcia, and Ricardo M. Biondi -- Affinity purification of protein kinases that adopt a specific inactive conformation / Pratistha Ranjitkar and Dustin J. Maly -- Determination of the kinetics and thermodynamics of ligand binding to a specific inactive conformation in protein kinases / Sanjay B. Hari, Pratistha Ranjitkar, and Dustin J. Maly -- Purification and specific assays for measuring APE-1 endonuclease activity / Adrian Esqueda [and others] -- In vitro screening to identify drug-resistant mutations for target-directed chemotherapeutic agents / Mohammad Azam -- Utilizing antagomiR (antisense microRNA) to knock down microRNA in murine bone marrow cells / Chinavenmeni S. Velu and H. Leighton Grimes -- Synthesis, conjugation, and labeling of multifunctional pRNA nanoparticles for specific delivery of siRNA, drugs, and other therapeutics to target cells / Peixuan Guo [and others] -- Mouse models for tumor metastasis / Shengyu Yang, J. Jillian Zhang, and Xin-Yun Huang.
520 ## - SUMMARY, ETC.
Summary, etc. Over the past three decades there have been new developments in therapeutic drug design. In \\\\\\\Rational Drug Design: Methods and Protocols\\\\\\\, expert researchers in the field detail many of the methodologies used to study rational drug design. These include methods such as virtual screening of chemical hits, rational lead discovery by high throughput screening, combinatorial and fragment based lead generation, peptide based drug discovery, and animal models of lead validation. Written in the highly successful \\\\\\\Methods in Molecular Biology [trademark]\\\\\\\ series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and key tips on troubleshooting and avoiding known pitfalls. Authoritative and practical, \\\\\\\Rational Drug Design: Methods and Protocols\\\\\\\ seeks to aid scientists in the further study of rational drug design and future drug discovery.
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Drugs -- Design. Arzneimitteldesign Drug Design.
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Book
Holdings
Withdrawn status Lost status Damaged status Not for loan Home library Current library Shelving location Date acquired Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
        Dept. of Computational Biology and Bioinformatics Dept. of Computational Biology and Bioinformatics Processing Center 01/09/2015   615.19 RAT DCB2415 01/09/2015 19/07/2019 Book